TORONTO, Aug. 11 /CNW/ - Novadaq Technologies Inc. (TSX: NDQ) today
reported its results for the second quarter ended June 30, 2005. During the
quarter, Novadaq completed its initial public offering (IPO) and began trading
its shares on the Toronto Stock Exchange under the symbol "NDQ".
"The closing of our IPO solidifies our financial position and will allow
us to expedite the execution of the SPY(TM) System commercialization and the
clinical development of the OPTTX(TM) System", said Arun Menawat, President
and CEO of Novadaq Technologies Inc. "This first quarter as a public company
was a very active one. We completed a strategic launch of the SPY System to
six prominent cardiac centers. We also negotiated a North American
distribution agreement with a leading cardiovascular multi-national partner to
distribute this innovative vascular imaging technology, which in the coming
quarters will facilitate a broader launch of the SPY System."
Key Developments
- Installed the SPY System in five strategic centers, including: The
Cleveland Clinic Foundation, Medical City Dallas, The Methodist
Hospital's Debakey Heart Institute, Lenox Hill and Stanford. Within
each center, physicians have recognized the value of information the
SPY System provides and continue to use this technology in their
procedures. A sixth hospital was added to the list in June with the
installation of the SPY System at the Enloe Medical Center in Chico,
California.
- Signed a strategic North American distribution agreement with the
Sorin Group to accelerate the penetration of the SPY System into the
United States cardiac surgery market. One of the key assets Sorin, a
world leader in the development of medical technologies for cardiac
surgery, brings to this emerging partnership is the strength of its
relationships with cardiac surgeons and operating room teams
throughout the United States.
- Finalized a United States service agreement with KODAK to provide
on-going service and maintenance for the SPY System.
- Received a patent grant for the SPY Intra-operative Imaging device and
procedure, a technology exclusively licensed from the National
Research Council of Canada. The U.S. patent is titled "Method and
Apparatus For Performing Intra-Operative Angiography".
- Continued to advance the progress of the OPTTX System with the
initiation of a 30 patient phase II study at Toronto Western Hospital,
Toronto, Canada led by Patricia Harvey, MD, a leading retinal
specialist. The study in Toronto is designed to demonstrate the
effectiveness of the OPTTX System in improving the delivery and
clinical outcomes of feeder vessel therapy (FVT), a known and
medically accepted treatment for Wet AMD.
Financial Results
Revenue in 2005 Q2 was $64,057, representing an increase of $51,341, over
revenue in 2004 Q2 of $12,716. $45,600 of this increase is attributable to
increased procedural revenue generated by SPY imaging devices installed in the
United States during 2005 Q2. The SPY System received regulatory clearance in
the United States in January 2005; the first device was installed in the
United States in March 2005 and; as at June 30, 2005 there were a total of 6
SPY imaging devices installed in the United States.
Cost of sales increased by $35,264 to $41,271 in 2005 Q2 as compared to
$6,007 in 2004 Q2. Gross profit for the period increased by $16,077. As a
percentage of sales, gross margin decreased to 36% in 2005 Q2 from 53% in 2004
Q2. The decrease in gross profit percentage is attributable primarily to one
time royalties and installation costs associated with the placement of SPY
imaging devices in 2005 Q2. These costs will become less significant as the
installation base grows.
Sales and marketing expenses increased to $300,889 in 2005 Q2 from
$34,320 in 2004 Q2. The increase in sales and marketing expenses was a result
of the commercial launch of the SPY System in the United States in March 2005,
and included an increase in employee and related office and travel costs -
(approximately $90,000); market development costs - (approximately $63,000);
marketing materials and advertising - (approximately $35,000) and trade shows
costs (approximately $78,000).
Research and development expenses increased by $731,240, to $948,924 in
2005 Q2 from $217,684 in 2004 Q2. This increase related primarily to costs
incurred to design and build next generation OPTTX devices for use in clinical
trials (increase of approximately $408,000), which are currently in the
testing phase. The overall increase also reflects the addition of engineering
staff to support the design efforts, and clinical staff to plan and execute
OPTTX trials (increase of approximately $187,000); as well as a significant
increase in patent costs (increase of approximately $122,000). The increase in
patent costs relates to additional SPY and OPTTX patents filed during 2005 Q2.
General and administration expenses increased by $805,972, to $1,255,573
in 2005 Q2 from $449,601 in 2004 Q2. Approximately $738,000 of this increase
is attributable to increased stock based compensation expense which related to
647,070 employee stock options which vested in 2005 Q2, primarily as a result
of the Company's initial public offering on June 10, 2005. General and
administration employee cost also increased by $58,000 to support the United
States commercial launch of the SPY System, the Company's increased level of
research and development activity, and to add infrastructure appropriate for a
public company. Insurance and other administrative costs increased by
approximately $81,000. These increases were partially offset by a reduction in
legal fees due to the settlement of litigation in June 2004.
Depreciation expense decreased by $9,259 from 2004 Q2 to 2005 Q2 as
certain SPY imaging devices that were being used in research and development
in 2004 Q2, were converted to revenue producing assets during 2005 Q2.
Amortization of these devices was included in depreciation expense in 2004 Q2
and cost of sales in 2005 Q2. Amortization increased by $6,663 from 2004 Q2 to
2005 Q2 as a result of license payments made in the second half of 2004 which
are capitalized and amortized.
Interest income increased by $87,061 from 2004 Q2 to 2005 Q2 as a result
of the increase in cash and short term investment balances following the
financing completed in July 2004, and as a result of the further increase in
cash and short-term investment balances following the completion of the
Company's initial public offering on June 10, 2005.
Net loss increased by $1,472,216 to $2,283,999 in 2005 Q2 from $811,783
in 2004 Q2. The increase in net loss related primarily to increases in sales
and marketing expenses (approximately $267,000); research and development
expenses (approximately $731,000) and increased general and administrative
expenses (approximately $806,000, of which approximately $738,000 related to
the vesting of outstanding stock options following the completion of the
Company's initial public offering), and was partially offset by increased
foreign exchange gains (approximately $225,000), and increased interest income
(approximately $87,000).
On June 30, 2005 the Company had cash, cash equivalents and short-term
investments totaling $26.7 million compared to $9.4 million at December 31,
2004. On June 10th, 2005 the Company completed an initial public offering for
total gross proceeds of approximately $20.1 million.
The number of common shares outstanding as of June 30, 2005 was
17,984,950 common shares.
Conference call
Novadaq will host a conference call on Friday, August 12, 2005 at
10:00 a.m. ET to discuss its second quarter 2005 results. To access the
conference call by telephone, dial 1-800-240-5318. Please connect
approximately ten minutes prior to the beginning of the call to ensure
participation. The conference call will be archived for replay until
August 19, 2005 at midnight. To access the archived conference call, dial
416-640-1917 or 1-877-289-8525 enter the reservation number 21132810 followed
by the number sign.
About Novadaq Technologies
Novadaq(TM) Technologies (TSX: NDQ) develops and commercializes medical
devices based on its proprietary imaging platform for the diagnosis and
treatment of human vascular and ophthalmic diseases and conditions. Novadaq's
SPY System enables surgeons to visually assess coronary vasculature and bypass
graft functionality during the course of CABG surgery. Novadaq's ophthalmic
product, OPTTX(TM) System, is aimed at the diagnosis, evaluation and treatment
of Wet Age Related Macular Degeneration (AMD) by using the same core imaging
technology that is used in the SPY. The OPTTX System is currently being
evaluated in clinical trials.
For more information, please visit the company's website at
www.novadaq.com.
Certain statements included in this press release may be considered
forward-looking. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results, performance or
achievements to be materially different from those implied by such statements,
and therefore these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on Novadaq's
current beliefs as well as assumptions made by and information currently
available to Novadaq and relate to, among other things, anticipated financial
performance, business prospects, strategies, regulatory developments, market
acceptance and future commitments. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date
of this press release. Due to risks and uncertainties, including the risks and
uncertainties identified by Novadaq in its public securities filings; actual
events may differ materially from current expectations. Novadaq disclaims any
intention or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.
Summary financial statements attached:
For complete financial statements please go to www.sedar.com
<<
NOVADAQ TECHNOLOGIES INC.
Incorporated under the laws of Canada
BALANCE SHEETS
(expressed in U.S.$)
Unaudited
As at As at
June 30, December 31,
2005 2004
$ $
-------------------------------------------------------------------------
ASSETS
Current
Cash and cash equivalents 157,269 434,380
Short-term investments 26,567,149 8,963,894
Accounts receivable 57,179 1,082,659
Investment tax credits receivable 39,236 54,468
Prepaid expenses and other receivables 420,854 58,644
Inventory 74,581 65,529
-------------------------------------------------------------------------
Total current assets 27,316,268 10,659,574
-------------------------------------------------------------------------
Property, plant and equipment, net 125,861 41,542
Deferred charges 15,137 19,015
Licenses, net 3,249,655 3,336,618
-------------------------------------------------------------------------
30,706,921 14,056,749
-------------------------------------------------------------------------
-------------------------------------------------------------------------
LIABILITIES AND SHAREHOLDERS' EQUITY
Current
Accounts payable and accrued liabilities 1,319,014 478,692
Current portion of deferred revenue 54,852 37,286
-------------------------------------------------------------------------
Total current liabilities 1,373,866 515,978
-------------------------------------------------------------------------
Deferred revenue 40,464 59,206
-------------------------------------------------------------------------
Total liabilities 1,414,330 575,184
-------------------------------------------------------------------------
Shareholders' equity
Share capital 46,213,640 27,966,017
Contributed surplus 3,349,831 2,280,891
Deficit (20,270,880) (16,765,343)
-------------------------------------------------------------------------
Total shareholders' equity 29,292,591 13,481,565
-------------------------------------------------------------------------
30,706,921 14,056,749
-------------------------------------------------------------------------
-------------------------------------------------------------------------
NOVADAQ TECHNOLOGIES INC.
STATEMENTS OF LOSS AND DEFICIT
(expressed in U.S.$)
Unaudited
Three months ended Six months ended
June 30, June 30,
2005 2004 2005 2004
$ $ $ $
-------------------------------------------------------------------------
Revenue 64,057 12,716 219,475 36,663
Cost of sales 41,271 6,007 77,570 23,159
-------------------------------------------------------------------------
Gross profit 22,786 6,709 141,905 13,504
-------------------------------------------------------------------------
Operating expenses
Sales and marketing 300,889 34,320 402,621 81,543
Research and
development 948,924 217,684 1,667,573 573,483
General and
administration 1,255,573 449,601 1,689,146 837,631
Depreciation 3,702 12,961 11,968 29,875
Amortization 106,680 100,017 211,963 200,033
Loss (gain) on
foreign exchange (218,829) 7,002 (211,354) 3,345
-------------------------------------------------------------------------
2,396,938 821,584 3,771,917 1,725,910
-------------------------------------------------------------------------
Loss before the
following (2,374,152) (814,875) (3,630,012) (1,712,406)
Interest income 90,153 3,092 124,475 3,902
-------------------------------------------------------------------------
Net loss for the
year (2,283,999) (811,783) (3,505,537) (1,709,314)
Deficit, beginning
of year (17,986,881) (14,890,009) (16,765,343) (13,992,478)
-------------------------------------------------------------------------
Deficit, end
of year (20,270,880) (15,701,792) (20,270,880) (15,701,792)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Basic and fully
diluted loss
per share (0.14) (0.06) (0.23) (0.14)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
NOVADAQ TECHNOLOGIES INC.
STATEMENTS OF CASH FLOWS
(expressed in U.S.$)
Unaudited
Three months ended Six months ended
June 30, June 30,
2005 2004 2005 2004
$ $ $ $
-------------------------------------------------------------------------
OPERATING ACTIVITIES
Net loss for
the period (2,283,999) (811,783) (3,505,537) (1,709,314)
Add (deduct) items
not involving cash
Depreciation and
amortization 18,421 119,916 235,307 240,184
Stock based
compensation 908,331 170,000 1,068,940 340,000
-------------------------------------------------------------------------
(1,257,247) (521,867) (2,201,290) (1,129,130)
Net change in
non-cash working
capital balances
related to
operations 307,541 (55,310) 1,507,474 102,624
-------------------------------------------------------------------------
Cash (used) in
operating activities (949,706) (577,176) (693,816) (1,026,506)
-------------------------------------------------------------------------
FINANCING ACTIVITIES
Issuance of common
shares 18,247,623 - 18,247,623 -
-------------------------------------------------------------------------
Cash provided by
financing
activities 18,247,623 - 18,247,623 -
-------------------------------------------------------------------------
INVESTING ACTIVITIES
Purchase of
property, plant
and equipment (89,566) - (102,663) (31,068)
Purchase of licenses (125,000) - (125,000) -
Investments in
short-term
investments, net (17,541,464) 542,839 (17,603,255) 999,625
-------------------------------------------------------------------------
Cash provided by
(used in)
investing (17,756,030) 542,839 (17,830,918) 968,557
-------------------------------------------------------------------------
Net increase
(decrease) in
cash and cash
equivalents
during the period (458,113) (34,337) (277,111) (57,951)
Cash and cash
equivalents,
beginning of period 615,382 124,178 434,380 147,790
-------------------------------------------------------------------------
Cash and cash
equivalents,
end of period 157,269 89,841 157,269 89,841
-------------------------------------------------------------------------
-------------------------------------------------------------------------
>>
%SEDAR: 00022069E
Novadaq Reports Financial Results For Second Quarter Of 2005
Novadaq Technologies Inc. on 6ix
Earlier from Novadaq Technologies
- Novadaq to hold second quarter 2005 conference call and webcast
- Novadaq Receives U.S. Patent for Intra-Operative Imaging Procedure Using the SPY System
- Novadaq, Sorin Group and Kodak Sign Strategic Agreements for SPY, an Intra-operative Imaging System to Benefit Heart Surgery
Later from Novadaq Technologies
- Novadaq Technologies Inc. - Q2 Earnings Announcement Webcast - August 12, 2005
- Novadaq to present at Sachs-Bloomberg and BioContact
- Novadaq Establishes United States Subsidiary Achieves September's SPY Placement Goal
- Novadaq Adds Co-Chief Medical Advisors to Cardiac Team
- Novadaq to hold third quarter 2005 conference call and webcast
Follow Novadaq Technologies into a list and get an email when it puts out news.
Follow Novadaq Technologies